1型糖尿病の小児患者における臨床プロファイル,血糖値,低血糖症の関係
Andreea Morar-Stan1, Luminița Dobrotă1, Anișoara Răduțu2
1Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550024 Sibiu, Romania.
Journal of clinical medicine
|February 13, 2026
まとめ
変数係数 (%CV) と日平均グルコース (MDG) は,1型糖尿病の小児における低血糖リスクを予測する. %CVを36%以下に保つことは,小児患者の低血糖症リスクを最小限に抑えるために重要です.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 小児科は小児科です.
- メタボリック障害 メタボリック障害
背景:
- 子供の1型糖尿病 (T1D) の管理には,低血糖症を予防するために注意深いモニタリングが必要です.
- 継続的なグルコースモニタリング (CGM) は,血糖コントロールとリスクを評価するための貴重なデータを提供します.
研究 の 目的:
- 小児T1D患者における低血糖リスクに対する臨床およびCGMパラメータの予測的役割を評価する.
- 軽度および臨床的に有意な低血糖症を予測するための重要な指標を特定する.
主な方法:
- CGMを使用した71人の小児T1D患者のコホートは,少なくとも6ヶ月間追跡されました.
- 分析されたパラメータには,年齢,BMI,範囲内の時間,日平均グルコース (MDG),および変数係数 (%CV) が含まれています.
- 低血糖症は,3.9 mmol/L (軽度) と3.0 mmol/L (有意) 以下の時間として定義されました.
主要な成果:
- 低いMDGと高い%CVは,低血糖症と有意に関連していました.
- %CVは,両方の低血糖値の支配的な予測因子として浮上した.
- 7歳未満の患者は,低血糖エピソードの最も高い頻度を示しました.
- 特定の%CV (<36.15%) とMDG (>7.16 mmol/L) の値が,低血糖症リスクの低下のために特定されました.
結論:
- %CVとMDGは,小児T1Dにおける低血糖リスクの主要な予測因子である.
- 36%未満の%CVは,低血糖症を最小限に抑えるために推奨されます.
- 年齢も要因であり,幼い子供 (<7歳) はより感受性がある.
関連する概念動画
Pharmacokinetics in Pediatric Patients: Drug Excretion
279
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Pediatric Patients: Drug Distribution
334
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism
247
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
247
Hypoglycemia and Glucagon
1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
311
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
311


